Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Torres, 2018, Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia, ERJ Open Res, 4, 00028, 10.1183/23120541.00028-2018 Cillóniz, 2019, An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria, Curr Opin Infect Dis, 32, 656, 10.1097/QCO.0000000000000596 Bassetti, 2016, Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?, Crit Care, 20, 19, 10.1186/s13054-016-1197-5 Özvatan, 2016, Nosocomial Acinetobacter pneumonia: treatment and prognostic factors in 356 cases, Respirology, 21, 363, 10.1111/resp.12698 Timsit, 2019, Rationalizing antimicrobial therapy in the ICU: a narrative review, Intensive Care Med, 45, 172, 10.1007/s00134-019-05520-5 Vazquez Guillamet, 2018, Acinetobacter pneumonia: improving outcomes with early identification and appropriate therapy, Clin Infect Dis, 67, 1455, 10.1093/cid/ciy375 Micek, 2015, An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance, Crit Care, 19, 219, 10.1186/s13054-015-0926-5 Timsit, 2017, How should we treat hospital-acquired and ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae?, Semin Respir Crit Care Med, 38, 287, 10.1055/s-0037-1603112 Kalil, 2016, Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis, 63, e61, 10.1093/cid/ciw353 Nicolau, 2008, Pharmacokinetic and pharmacodynamic properties of meropenem, Clin Infect Dis, 47, S32, 10.1086/590064 Lynch, 2017, Infections due to Acinetobacter baumannii in the ICU: treatment options, Semin Respir Crit Care Med, 38, 311, 10.1055/s-0037-1599225 Osthoff, 2016, Prolonged administration of β-lactam antibiotics—a comprehensive review and critical appraisal, Swiss Med Wkly, 146 Kollef, 2019, Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial, Lancet Infect Dis, 19, 1299, 10.1016/S1473-3099(19)30403-7 Li, 2006, Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients, J Clin Pharmacol, 46, 1171, 10.1177/0091270006291035 Song, 2019, Is meropenem as a monotherapy truly incompetent for meropenem-nonsusceptible bacterial strains? A pharmacokinetic/pharmacodynamic modeling with Monte Carlo simulation, Front Microbiol, 10, 10.3389/fmicb.2019.02777 Frippiat, 2015, Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study, J Antimicrob Chemother, 70, 207, 10.1093/jac/dku354 Del Bono, 2017, Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: should we get to the PK/PD root of the paradox?, Virulence, 8, 66, 10.1080/21505594.2016.1213476 Ito, 2017, In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria, Antimicrob Agents Chemother, 62, e01454 Karlowsky, 2019, In vitro activity of cefiderocol, a siderophore cephalosporin, against Gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015–2016: SIDERO-WT-2015, Int J Antimicrob Agents, 53, 456, 10.1016/j.ijantimicag.2018.11.007 Hackel, 2018, In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of Gram-negative bacilli collected worldwide in 2014 to 2016, Antimicrob Agents Chemother, 62, e01968, 10.1128/AAC.01968-17 Katsube, 2019, Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin, Clin Infect Dis, 69, S552, 10.1093/cid/ciz828 Portsmouth, 2018, Cefiderocol versus imipenem–cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial, Lancet Infect Dis, 18, 1319, 10.1016/S1473-3099(18)30554-1 Echols, 2019, Pathogen-focused clinical development to address unmet medical need: cefiderocol targeting carbapenem resistance, Clin Infect Dis, 69, S559, 10.1093/cid/ciz829 Bassetti, 2019, Designing a pathogen-focused study to address the high unmet medical need represented by carbapenem-resistant Gram-negative pathogens—the international, multicenter, randomized, open-label, phase 3 CREDIBLE-CR study, Infect Drug Resist, 12, 3607, 10.2147/IDR.S225553 2020 Micek, 2015, Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification, Infect Control Hosp Epidemiol, 36, 1190, 10.1017/ice.2015.167 Torres, 2018, Ceftazidime–avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial, Lancet Infect Dis, 18, 285, 10.1016/S1473-3099(17)30747-8 Torres, 2019, Randomized trial of ceftazidime–avibactam vs meropenem for treatment of hospital-acquired and ventilator-associated bacterial pneumonia (REPROVE): analyses per US FDA-specified end points, Open Forum Infect Dis, 6, 10.1093/ofid/ofz149 Mehta, 2018, Beware of broad-spectrum generalizations: ceftazidime–avibactam compared to meropenem for the treatment of Gram-negative pneumonia, J Emerg Crit Care Med, 2, 45, 10.21037/jeccm.2018.05.02 Furtado, 2015, Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital, Rev Soc Bras Med Trop, 48, 539, 10.1590/0037-8682-0122-2015